Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.
暂无分享,去创建一个
I. E. Smith | James M. Woolven | O. Singh | G. Wayne | S. Lynn | J. Harling | D. Somers | Timothy Longstaff | C. Mooney | A. C. Maxwell | A. Campbell | Christopher J. Tame | Callum Scullion | A. Champigny | C. Alder | A. Deakin | Caroline Wilson | Martin Ambler | Carol A Harris
[1] David R. Anderson,et al. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay. , 2012, Journal of medicinal chemistry.
[2] D. Scott,et al. Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.
[3] A. August,et al. Regulation of T-cell Responses and Disease by Tec Kinase Itk , 2012, International reviews of immunology.
[4] F. Giles,et al. Targeting aurora kinases in cancer treatment. , 2011, Current drug targets.
[5] Paul Bamborough,et al. Selectivity of kinase inhibitor fragments. , 2011, Journal of medicinal chemistry.
[6] J. Grasis,et al. Itk: The Rheostat of the T Cell Response , 2011, Journal of signal transduction.
[7] A. Tanner,et al. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. , 2011, Journal of medicinal chemistry.
[8] J. Woska,et al. 5-Aminomethylbenzimidazoles as potent ITK antagonists. , 2009, Bioorganic & medicinal chemistry letters.
[9] Mohane Selvaraj Coumar,et al. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. , 2009, Journal of medicinal chemistry.
[10] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[11] A. Doweyko,et al. Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[12] Daniel A. Erlanson,et al. Fragment‐Based Drug Discovery. , 2004 .
[13] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[14] W. Earnshaw,et al. The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.
[15] Duncan E McRee,et al. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. , 2002, Structure.
[16] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[17] H. Lo. Itk inhibitors : a patent review , 2010 .
[18] E. Bush,et al. Data normalization before statistical analysis: keeping the horse before the cart. , 1988, Trends in pharmacological sciences.